Petrausch Ulf, Poehlein Christian H, Jensen Shawn M, Twitty Chris, Thompson James A, Assmann Ilka, Puri Sachin, LaCelle Michael G, Moudgil Tarsem, Maston Levi, Friedman Kevin, Church Sarah, Cardenas Elisa, Haley Daniel P, Walker Edwin B, Akporiaye Emmanuel, Weinberg Andrew D, Rosenheim Sidney, Crocenzi Todd S, Hu Hong-Ming, Curti Brendan D, Urba Walter J, Fox Bernard A
Robert W. Franz Cancer Research Center, Earle. A. Chiles Research Institute, 4805 NE Glisan Street, Portland, OR 97213, USA.
Curr Mol Med. 2009 Aug;9(6):673-82. doi: 10.2174/156652409788970670.
Since multiple lines of experimental and clinical data clearly identified regulatory T cells as an integral part of the immune response, these cells have become a major focus of investigation in tumor immunology. Regulatory T cells are in place to dampen ongoing immune responses and to prevent autoimmunity, but they also have profound effects in blocking therapeutic anti-tumor activity. Therefore regulatory T cells are seen as a major hurdle that must be overcome in order for cancer immunotherapy to reach its therapeutic potential. Regulatory T cells are heterogeneous with sub-populations that exhibit distinct functional features. Here we will review the individual sub-populations in regards to their mode of action and their potential impact on blocking anti-tumor immunity. Approaches to measure function and frequency of regulatory T cells in model systems and clinical trails will be discussed. Finally, we will describe possible ways to interfere with regulatory T cell-mediated immune suppression with the focus on recent pre-clinical and clinical findings.
由于多条实验和临床数据明确将调节性T细胞确定为免疫反应的一个组成部分，这些细胞已成为肿瘤免疫学研究的主要焦点。调节性T细胞的作用是抑制正在进行的免疫反应并预防自身免疫，但它们在阻断治疗性抗肿瘤活性方面也有深远影响。因此，调节性T细胞被视为癌症免疫疗法发挥其治疗潜力必须克服的主要障碍。调节性T细胞是异质性的，其亚群表现出不同的功能特征。在这里，我们将回顾各个亚群的作用方式及其对阻断抗肿瘤免疫的潜在影响。还将讨论在模型系统和临床试验中测量调节性T细胞功能和频率的方法。最后，我们将重点关注最近的临床前和临床研究结果，描述干扰调节性T细胞介导的免疫抑制的可能方法。
